ArticleDiscover oncology2025
CCDC86 modulates immune cell infiltration and disease progression in head and neck squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) is a prevalent and aggressive cancer with poor prognosis despite advancements in treatment. The immune system plays a crucial role in HNSCC progression, yet the specific mechanisms linking immune cells to tumor development remain poorly understood. Coiled-coil domain-containing protein 86 (CCDC86) has been implicated in immune dysregulation, but its role in HNSCC has not been explored. This study investigates the expression of CCDC86 in HNSCC, its association with immune infiltration, and its potential as a prognostic biomarker.
methodsThis study integrates single-cell RNA sequencing (scRNA-seq), The Cancer Genome Atlas (TCGA) data, and Mendelian randomization (MR) analysis. scRNA-seq datasets from normal oral mucosa and HNSCC tissues were used to analyze CCDC86 expression in different cell populations. TCGA data were employed to assess the correlation between CCDC86 expression and clinicopathological features of HNSCC. MR analysis was conducted to explore the causal relationship between CCDC86 and immune cell phenotypes in HNSCC.
resultsCCDC86 was significantly overexpressed in HNSCC tissues compared to normal tissues. High expression of CCDC86 was associated with poor prognosis, correlating with histological grade, clinical stage, and survival outcomes. Gene ontology (GO) and KEGG pathway analyses revealed that CCDC86 is involved in immune cell activation and receptor complex assembly. A negative correlation between CCDC86 expression and immune infiltration, especially in dendritic cells (DCs) and T cells, was observed. MR analysis confirmed a causal relationship between CCDC86 expression and HNSCC risk, with a notable effect on immune cell populations, particularly myeloid DCs.
conclusionCCDC86 expression is upregulated in HNSCC and is associated with adverse clinicopathological features and poor prognosis. CCDC86 modulates immune cell infiltration, particularly inhibiting the function of conventional dendritic cells. These findings suggest that CCDC86 could serve as a prognostic biomarker and a potential therapeutic target for HNSCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.